Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
11.35
+0.38 (3.46%)
At close: May 12, 2025, 4:00 PM
10.73
-0.62 (-5.46%)
After-hours: May 12, 2025, 6:37 PM EDT
Mesoblast Revenue
Mesoblast had revenue of $3.16M in the half year ending December 31, 2024, a decrease of -7.77%. This brings the company's revenue in the last twelve months to $5.67M, down -24.07% year-over-year. In the fiscal year ending June 30, 2024, Mesoblast had annual revenue of $5.90M, down -21.32%.
Revenue (ttm)
$5.67M
Revenue Growth
-24.07%
P/S Ratio
247.71
Revenue / Employee
$77,671
Employees
73
Market Cap
1.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
MESO News
- 7 days ago - Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials - Seeking Alpha
- 13 days ago - Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025 - GlobeNewsWire
- 14 days ago - Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board - GlobeNewsWire
- 26 days ago - Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives - GlobeNewsWire
- 5 weeks ago - Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs - GlobeNewsWire
- 5 weeks ago - Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure - GlobeNewsWire
- 6 weeks ago - First Three Children to Commence Treatment With Ryoncil® - GlobeNewsWire
- 6 weeks ago - Ryoncil® is Now Available for Purchase in the United States - GlobeNewsWire